A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1–associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study

BACKGROUND: Activation of the mammalian target of rapamycin (mTOR) pathway is observed in neurofibromatosis type 1 (NF1) associated low-grade gliomas (LGGs), but agents that inhibit this pathway, including mTOR inhibitors, have not been studied in this population. We evaluate the efficacy of the ora...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Ullrich, Nicole J, Prabhu, Sanjay P, Reddy, Alyssa T, Fisher, Michael J, Packer, Roger, Goldman, Stewart, Robison, Nathan J, Gutmann, David H, Viskochil, David H, Allen, Jeffrey C, Korf, Bruce, Cantor, Alan, Cutter, Gary, Thomas, Coretta, Perentesis, John P, Mizuno, Tomoyuki, Vinks, Alexander A, Manley, Peter E, Chi, Susan N, Kieran, Mark W
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Pediatric Neuro-Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7566451/
https://ncbi.nlm.nih.gov/pubmed/32236425
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa071
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados